List of most important publications 2002-2008:

1. Schaich M, Kestel L, Pfirrmann M, Robel K, Illmer T, Kramer M, Dill C, Ehninger G, Schackert G, Krex D. A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temezolomide treatment in glioblastoma patients. Ann Oncol 2008 Aug 7. [Epub ahead of print]

2. Fierro FA, Taubenberger A, Puech PH, Ehninger G, Bornhauser M, Muller DJ, Illmer T. BCR/ABL expression of myeloid progenitors increases beta1-integrin mediated adhesion to stromal cells. J Mol Biol. 2008; 377:1082-93.

3. Schaich M, Schlenk RF, Al-Ali HK, Döhner H, Ganser A, Heil G, Illmer T, Krahl R, Krauter J, Sauerland C, Büchner T, Ehninger G. Prognosis of acute myeloid leukemia patients up to 60 yaers of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. Haematologica. 2007; 92:763-70.

4. Dransfeld CL*, Schaich M*, Ho AD, Thiede C, Ehninger G, Mahlknecht U. Class I HDAC SNP analysis in healthy donors compared to AML patients. Leukemia. 2007; 21:1587-90. * both authors contributed equally.

5. Illmer T, Schaich M, Ehninger G, Thiede C; DSIL2003 AML study group. Tyrosine kinase mutations of JAK2 are rare events in AML but influence prognosis of patients with CBF leukemias. Haematologica. 2007; 92:137-8.

6. Schaich M, Soucek S, Thiede C, Ehninger G, Illmer T on behalf of the SHG AML96 study group. MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Haematol 2005; 128: 324-332.

7. Illmer T, Thiede C, Fredersdorf A, Stadler S, Neubauer A, Ehninger G, Schaich M. Activation of the RAS pathway is predictive for chemosensitive phenotype of AML blasts. Clin Cancer Res 2005; 11: 3217-3224.

8. Schaich M, Koch R, Soucek S, Repp R, Ehninger G, Illmer T. A sensitive model for prediction of relapse in adult acute myeloid leukaemia with t(8;21) using white blood cell count, CD56 and MDR1 gene expression at diagnosis. Br J Haematol 2004; 125: 477-479. 

9. Illmer T, Schaich M, Platzbecker U, Freiberg-Richter J, Oelschlagel U, von Bonin M, Pursche S, Bergemann T, Ehninger G, Schleyer E. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004; 18: 401-408.

10. Schaich M, Harbich-Brutscher E, Pascheberg U, Mohr B, Soucek S, Ehninger G, Illmer T. Association of specific cytogenetic aberrations with mdr1 gene expression in adult myeloid leukemia and its implication in treatment outcome. Haematologica 2002; 87: 455-464.

11. Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S, Freund D, Schäkel U, Ehninger G, Schaich M. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 2002; 62: 4955-4962.

12. Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, Wermke M, Bornhäuser M, Ritter M, Neubauer A, Ehninger G, Illmer T. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326-4335.